Nebicip 5 mg Cipla
€34.00
Introducing Nebicip 5 mg Cipla: A Powerful Solution for Blood Pressure Management
Nebicip 5 mg Cipla is a premium medication designed to effectively manage blood pressure levels. This product, containing the active substance nebivolol, belongs to the beta-blocker family and is renowned for its ability to lower both systolic and diastolic blood pressure. Utilised primarily in patients with hypertension, Nebicip helps maintain a stable cardiovascular system, contributing to overall heart health. The selective action of nebivolol ensures that it targets the necessary receptors in the heart, providing an efficient approach to blood pressure control that is both safe and well-tolerated by most patients.
Key Advantages of this Medication for Blood Pressure Control
Nebicip 5 mg Cipla offers numerous advantages that make it an optimal choice for individuals looking to manage their blood pressure effectively. Some key benefits include its low risk of hepatotoxicity and minimal water retention, which makes it suitable for long-term use without raising concerns about liver health or unwanted fluid accumulation. Written below are some of the prominent benefits of Nebicip that can significantly enhance the quality of life for those dealing with hypertension:
- Effective reduction of blood pressure, aiding in heart health.
- Minimal side effects compared to many other blood pressure medications.
- Long half-life of approximately 10 hours, ensuring stable effects throughout the day.
- Easier to adhere to dosage schedules, taking once daily at 2.5 to 10 mg.
These advantages make Nebicip an appealing option for patients who may struggle with the rigorous demands of managing their blood pressure. The careful formulation and research behind this medication position it as a reliable choice for long-term treatment.
The Practical Benefits and Long-term Effects of Nebicip 5 mg Cipla
Choosing Nebicip 5 mg Cipla for blood pressure management not only addresses immediate health needs but also fosters long-term health stability. Regular use of this medication contributes to a gradual but significant improvement in cardiovascular outcomes. Patients often experience not just a reduction in blood pressure; they may also notice enhanced overall wellbeing thanks to its ability to lower heart rate effectively.
Moreover, the regular monitoring of blood pressure and heart rate is essential during the treatment with Nebicip, ensuring that the desired outcomes align with health objectives. By maintaining blood pressure within healthy limits, patients can mitigate the risk of developing serious conditions like heart disease or stroke.
In summary, Nebicip 5 mg Cipla stands as a robust option for anyone looking to manage hypertension effectively. With its targeted action, minimal side effects, and ease of use, making it a smart choice for those who prioritise their heart health and overall wellness. Always consult a healthcare professional to determine the appropriate treatment plan tailored to individual health needs.
| Active substance | Nebivolol |
|---|---|
| Classification | Beta Blockers |
| Water Retention | Minimal |
| Hepatotoxicity | Low risk |
| Lab Test | Blood pressure monitoring and heart rate |
| Also known as | Nebivololum |
| WAREHOUSE | International Warehouse 1 |
| Blood pressure | Reduces systolic and diastolic blood pressure |
| Trade name | Bystolic, Nebilet |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | 1-(6-Fluorochroman-2-yl)-{[2-(6-fluorochroman-2-yl)ethoxy]methyl}-2,2-dimethyl-propan-1-amine |
| Formula | C22H25F2NO4 |
| Substance class | Beta blocker |
| Main action | Selective ОІ1 receptor antagonist |
| Half-life | Approximately 10 hours |
| Dosage (medical) | 2.5 to 10 mg once daily |
| Dosage (sports) | Not applicable |
| Effects | Lowers blood pressure, reduces heart rate |
| Side effects | Fatigue, dizziness, headache, nausea, diarrhea, bradycardia, dyspnea, edema |
| Use in sports | None, not used as a performance-enhancing drug |
| Manufacturer | Cipla |
| 5 |
|
0 |
| 4 |
|
0 |
| 3 |
|
0 |
| 2 |
|
0 |
| 1 |
|
0 |



Reviews
There are no reviews yet.